Try our Advanced Search for more refined results
Life Sciences
-
February 10, 2026
Lutnick Rules Out Creating Value-Based Fees For Patents
Commerce Secretary Howard Lutnick told a Senate panel Tuesday that the government is not planning to establish new fees for U.S. patents based on their value, saying the idea he was reportedly considering "is not going anywhere."
-
February 10, 2026
Lipid Testing Patents Recite Laws Of Nature, Judge Says
A Massachusetts federal judge has dismissed a company's infringement claims against a rival over patents that cover methods of testing for lysosomal storage disorders, ruling that the patents only cited patent-ineligible laws of nature.
-
February 10, 2026
Apple Again Pushes To Escape Masimo's $634M IP Verdict
Apple is doubling down on its bid to have U.S. District Judge James V. Selna relieve it from a jury's $634 million infringement verdict in litigation over its Apple Watch, saying Masimo Corp. relied on an improper and "shifting" definition of a dispositive term.
-
February 10, 2026
Pa. Hospital Settles Ex-Worker's ADA Suit Over CBD Gummy
UPMC Pinnacle Hospitals has settled a former employee's disability discrimination suit claiming he was unlawfully fired when he tested positive for cannabis because he took cannabidiol gummies used to treat his spinal condition.
-
February 10, 2026
Judge Questions Timing Of Case Against Harvard Researcher
A Massachusetts federal judge on Tuesday ordered the U.S. Attorney's Office to turn over materials related to its decision to prosecute a Harvard Medical School researcher and Russian national found with inert frog embryo specimens last year at Logan Airport, calling the timing of the case "a red flag."
-
February 10, 2026
Astellas Gets $90M From Lupin In Myrbetriq Patent Deal
Generic-drug maker Lupin Pharmaceuticals has inked a deal to pay $90 million to settle claims that it infringed patents held by rival Astellas Pharma Inc. covering name-brand bladder drug Myrbetriq.
-
February 10, 2026
Norton Rose Hires Cooley Life Sciences Duo In DC
Norton Rose Fulbright has hired two life sciences attorneys from Cooley LLP in Washington, D.C., who focus on biotech and pharmaceutical intellectual property matters, in a move the firm said is an investment in IP as a core practice.
-
February 10, 2026
Whooping Cough-Focused Biotech Wraps $115M Fundraise
Florida-based biotechnology company ILiAD Biotechnologies Inc. on Tuesday revealed that it wrapped its latest financing round after securing $115 million from investors, which will be used to advance development on a potential whooping cough vaccine.
-
February 09, 2026
Kurin Fights $1.6M IP Verdict As Rival Seeks More Damages
Kurin has urged a Delaware federal judge to overturn Magnolia Medical's $1.6 million patent verdict or order a new trial, while Magnolia Medical has asked the court to bar Kurin from selling allegedly infringing "Jet" blood-culture collection products and award it supplemental damages on Kurin's sales, plus ongoing royalties and interest.
-
February 09, 2026
Defendant Mix-Up Ends Biotech FCA Suit, For Now
A New York federal court ruled that a relator's False Claims Act suit failed to link claims of improper COVID-19 billing and other alleged schemes to defraud Medicare to the biotech company it named as a defendant, dismissing the complaint with leave to amend.
-
February 09, 2026
Italian Biathlete Lodges Appeal Of Olympic Doping Ban
Italian biathlete Rebecca Passler, who was booted from the Olympic team last week after a positive doping test, has appealed the decision to the Court of Arbitration for Sport, asserting that the test result arose from a contamination issue.
-
February 09, 2026
Fed. Circ. Sends Blood Pump Patent Fight Back To Mass.
The Federal Circuit on Monday reversed a lower court's ruling that Abiomed Inc. hasn't infringed five patents on blood pump systems and methods, while backing the part of the decision that cleared the medical device technology company of allegations it infringed a different patent.
-
February 09, 2026
Novo Nordisk Sues Hims & Hers Over Knockoff GLP-1
Novo Nordisk AS followed through on Monday in Delaware federal court on a plan it announced last week to sue telehealth company Hims & Hers Health Inc. over its marketing of what Novo Nordisk calls a knockoff version of its GLP-1 medications.
-
February 09, 2026
High Court Asked To Take Up Malpractice Case Against Akin
A former Cornell University graduate student wants the U.S. Supreme Court to review the dismissal of his suit accusing Akin Gump Strauss Hauer & Feld LLP attorneys of manipulating patent litigation to steal his DNA sequencing intellectual property.
-
February 09, 2026
Paul Weiss, Goodwin Steer Eli Lilly's $2.4B Orna Buy
Pharmaceutical giant Eli Lilly & Co., advised by Paul Weiss Rifkind Wharton & Garrison LLP, on Monday announced that it has agreed to buy Goodwin Procter LLP-led biotechnology firm Orna Therapeutics Inc. in a deal where Orna shareholders could receive up to $2.4 billion in cash.
-
February 06, 2026
Takeda Can't Ax Most Of Heartburn Drug Pay-For-Delay Suit
Takeda Pharmaceutical Co. and TWi Pharmaceuticals must face most of a proposed antitrust class action accusing them of delaying the release of the generic version of Takeda's heartburn medication Dexilant, causing Walgreens, Kroger and other retailers to pay more for the brand-name drug, a California federal judge ruled Friday.
-
February 06, 2026
Ga. Panel Backs Sperm Bank Win In 'Wrongful Birth' Case
A Georgia appeals court backed a win for sperm bank Xytex Corp. in consolidated litigation alleging the company sold sperm under false pretenses about the medical, psychological and social history of the donors.
-
February 06, 2026
HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight
U.S. Department of Health and Human Services general counsel Mike Stuart announced Friday that his office referred Hims & Hers Health Inc. to the U.S. Department of Justice for investigation, a day after Novo Nordisk A/S threatened litigation over what it called the telehealth company's "knockoff" version of its popular weight loss drug Wegovy.
-
February 06, 2026
NJ Judge Tosses Pacira Investor Suit Over Patent Loss
A New Jersey federal judge on Friday threw out an investor lawsuit against Pacira BioSciences Inc. after a court invalidated a patent for its key pain management drug, ruling that the pharmaceutical company was not required to disclose litigation setbacks it encountered before the final ruling.
-
February 06, 2026
Arizona Abortion Restrictions Found Unconstitutional
An Arizona state court permanently struck down a slew of restrictions on abortion care in the state, including an ultrasound mandate and a ban on the mailing of abortion pills, finding that the restrictions violate the right to abortion enshrined in the state's constitution.
-
February 06, 2026
PTAB Tosses 2nd Patent On Cologuard Colon Cancer Test
The Patent Trial and Appeal Board has found that Geneoscopy had shown that all the claims it challenged in a patent on Exact Sciences' colon cancer test Cologuard are invalid as obvious, months after the PTAB invalidated claims in a similar patent.
-
February 06, 2026
3rd Circ. Remands J&J Unit's Libel Suit Over Talc Study
Johnson & Johnson's talc liability unit will get another chance to pursue libel claims against a scientist over an article she wrote linking talcum power to mesothelioma, after the Third Circuit agreed to send the case back to New Jersey federal court.
-
February 06, 2026
TPG Hid Exactech Defects To Dodge Liability, Trust Alleges
The settlement trust of joint implant maker Exactech filed a billion-dollar lawsuit in Delaware Chancery Court against TPG Inc., accusing the private equity firm of controlling Exactech after buying it in 2018, concealing the implants' defects, delaying product recalls and pushing the company into Chapter 11 to avoid liability.
-
February 06, 2026
SEC Alleges Pharma Co. Misled Investors About Cancer Drug
The U.S. Securities and Exchange Commission is suing a Kentucky pharmaceutical company for securities fraud based on claims that the company raised $4.1 million by lying to investors about the status of its cancer treatment drug.
-
February 06, 2026
Beasley Allen Disqualified From NJ Talc Multicounty Litigation
A New Jersey state appeals court disqualified the Beasley Allen Law Firm from representing plaintiffs in multicounty litigation over Johnson & Johnson's talc-based baby powder, ruling Friday that a former Faegre Drinker Biddle & Reath LLP lawyer's collaborative efforts with the firm's attorneys violated ethics rules.
Expert Analysis
-
How Litigating Antitrust Fix Helped GTCR Prevail In Court
An Illinois federal judge's recent denial of the Federal Trade Commission's injunction request in the GTCR acquisition of Surmodics joins a developing series of cases in which deal parties have prevailed against government antitrust challenges by proposing a post-complaint fix and litigating the as-amended deal, say attorneys at Paul Weiss.
-
Series
Building With Lego Makes Me A Better Lawyer
Building with Lego has taught me to follow directions and adapt to unexpected challenges, and in pairing discipline with imagination, allows me to stay grounded while finding new ways to make complex deals come together, says Paul Levin at Venable.
-
The Rise Of Trade Secret Specificity As A Jury Question
Recent federal appellate court decisions have clarified that determining sufficient particularity under the Defend Trade Secrets Act is a question of fact and will likely become a standard jury question, highlighting the need for appropriate jury instructions that explicitly address the issue, says Amy Candido at Simpson Thacher.
-
Series
Law School's Missed Lessons: Networking 101
Cultivating a network isn't part of the law school curriculum, but learning the soft skills needed to do so may be the key to establishing a solid professional reputation, nurturing client relationships and building business, says Sharon Crane at Practising Law Institute.
-
Defeating Estoppel-Based Claims In Legal Malpractice Actions
State supreme court cases from recent years have addressed whether positions taken by attorneys in an underlying lawsuit can be used against them in a subsequent legal malpractice action, providing a foundation to defeat ex-clients’ estoppel claims, says Christopher Blazejewski at Sherin and Lodgen.
-
Trade Secret Rulings Reveal The Cost Of Poor Preparation
Two recent federal appellate decisions show that companies must be prepared to prove their trade secrets with specificity, highlighting how an asset management program that identifies key confidential information before litigation arises can provide the clarity and documentation that courts increasingly require, say attorneys at Mintz.
-
Series
The Biz Court Digest: How It Works In Massachusetts
Since its founding in 2000, the Massachusetts Business Litigation Session's expertise, procedural flexibility and litigant-friendly case management practices have contributed to the development of a robust body of commercial jurisprudence, say James Donnelly at Mirick O’Connell, Felicia Ellsworth at WilmerHale and Lisa Wood at Foley Hoag.
-
Why Appellees Should Write Their Answering Brief First
Though counterintuitive, appellees should consider writing their answering briefs before they’ve ever seen their opponent’s opening brief, as this practice confers numerous benefits related to argument structure, time pressures and workflow, says Joshua Sohn at the U.S. Department of Justice.
-
Navigating DEA Quotas: Key To Psychedelics Industry Growth
As new compounds like DOI enter the Schedule I landscape, manufacturers who anticipate U.S. Drug Enforcement Administration quota regulations, and build quota management into their broader strategy, will be best equipped to meet the growing demand, say Kimberly Chew at Husch Blackwell and Jaime Dwight at Promega.
-
Series
Mindfulness Meditation Makes Me A Better Lawyer
Mindful meditation enables me to drop the ego, and in helping me to keep sight of what’s important, permits me to learn from the other side and become a reliable counselor, says Roy Wyman at Bass Berry.
-
Growth, Harmonization In Focus As Hague System Turns 100
One hundred years after its establishment, the Hague System has grown into an important pillar of international design protection, offering a promising path toward even greater harmonization in design law as its geographic reach continues to expand, say attorneys at Sterne Kessler.
-
Lessons From 7th Circ. Decision Affirming $183M FCA Verdict
The Seventh Circuit's decision to uphold a $183 million False Claims Act award against Eli Lilly engages substantively with recurring materiality and scienter questions and provides insights into appellate review of complex trial court judgments, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Kimberly Friday at Osborn Maledon.
-
Opinion
Punitive Damages Awards Should Be Limited To 1st Instance
Recent verdicts in different cases against Johnson & Johnson and Monsanto showcase a trend of multiple punitive damages being awarded to different plaintiffs for the same course of conduct by a single defendant, a practice that should be deemed unconstitutional by the U.S. Supreme Court, says Jacob Mihm at Polales Horton.
-
How Calif. High Court Is Rethinking Forum Selection Clauses
Two recent cases before the California Supreme Court show that the state is shifting toward greater enforcement of freely negotiated forum selection clauses between sophisticated parties, so litigators need to revisit old assumptions about the breadth of California's public policy exception, says Josh Patashnik at Perkins Coie.
-
AI Litigation Tools Can Enhance Case Assessment, Strategy
Civil litigators can use artificial intelligence tools to strengthen case assessment and aid in early strategy development, as long as they address the risks and ethical considerations that accompany these uses, say attorneys at Barnes & Thornburg.